Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

biolab australia pty. ltd. - chlorine present as trichloroisocyanuric acid - tablet (inc. pellet, bolus, suppository, capsule) - chlorine present as trichloroisocyanuric acid mineral-chlorine-acid active 900.0 g/kg - algicide - swimming pool - algae | bacteria

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

biolab australia pty. ltd. - chlorine present as trichloroisocyanuric acid - tablet (inc. pellet, bolus, suppository, capsule) - chlorine present as trichloroisocyanuric acid mineral-chlorine-acid active 880.0 g/kg - algicide - swimming pool - algae | bacteria

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

biolab australia pty. ltd. - chlorine present as trichloroisocyanuric acid - tablet (inc. pellet, bolus, suppository, capsule) - chlorine present as trichloroisocyanuric acid mineral-chlorine-acid active 900.0 g/kg - algicide - swimming pool - algae | bacteria

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol tablets, 250 mg and 500 mg are indicated for the treatment of patients with primary biliary cholangitis (pbc). patients with complete biliary obstruction and known hypersensitivity or intolerance to ursodiol or any of the components of the formulation. risk summary available published data on the use of ursodiol in pregnant women derived from randomized controlled trials, observational studies, and case series collected over several decades have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. most of the reported exposures to ursodiol occurred in the second and third trimester of pregnancy. in animal reproduction studies, ursodiol had no adverse effects on embryo-fetal development when administered at doses greater than human therapeutic doses (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or ot

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol tablets, 250 mg and 500 mg are indicated for the treatment of patients with primary biliary cholangitis (pbc). patients with complete biliary obstruction and known hypersensitivity or intolerance to ursodiol or any of the components of the formulation. risk summary available published data on the use of ursodiol in pregnant women derived from randomized controlled trials, observational studies, and case series collected over several decades have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. most of the reported exposures to ursodiol occurred in the second and third trimester of pregnancy. in animal reproduction studies, ursodiol had no adverse effects on embryo-fetal development when administered at doses greater than human therapeutic doses (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or ot

Canada - English - Health Canada

boehringer ingelheim animal health canada inc. - firocoxib - tablet - 57mg - firocoxib 57mg - horses

United States - English - NLM (National Library of Medicine)

strides pharma science limited - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol tablets, 250 mg and 500 mg are indicated for the treatment of patients with primary biliary cholangitis (pbc). patients with complete biliary obstruction and known hypersensitivity or intolerance to ursodiol or any of the components of the formulation. risk summary available published data on the use of ursodiol in pregnant women derived from randomized controlled trials, observational studies, and case series collected over several decades have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. most of the reported exposures to ursodiol occurred in the second and third trimester of pregnancy. in animal reproduction studies, ursodiol had no adverse effects on embryo-fetal development when administered at doses greater than human therapeutic doses (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or ot

Canada - English - Health Canada

merck canada inc - belzutifan - tablet - 40mg - belzutifan 40mg

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - iron dextran complex; vitamin a palmitate; vitamin d3 = cholecalciferol; tocopheryl acetate (vitamin e) - parenteral liquid/solution/suspension - iron dextran complex mineral-iron active 100.0 mg/ml; vitamin a palmitate vitamin-a active 100000.0 iu/ml; vitamin d3 = cholecalciferol vitamin-d3 active 1000.0 iu/ml; tocopheryl acetate (vitamin e) vitamin-e active 10.0 mg/ml - nutrition & metabolism - pig - piglet | neonatal piglet | new born pig | sucker pig - iron & haemopoietic agent | anaemia | haemopoietic agents | hematinic | iron deficiency

Australia - English - Department of Health (Therapeutic Goods Administration)

osseo dental - 35310 - orthodontic appliance, retainer - clearcorrect retainers are clear, thin, plastic, thermoformed, removable orthodontic appliances used at the completion of orthodontically repositioned teeth as prescribed by a dentist or orthodontist. the retainers are indicated for the maintenance of teeth in their corrected positions following corrective orthodontic treatment. clearcorrect retainers can be used in conjunction with the clearcorrect orthodontic appliance system or prescribed by a dentist or orthodontist for the maintenance of teeth in their corrected positions following corrective orthodontic treatment using any other orthodontic procedure